2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0202R
    Irbesartan (Standard) 138402-11-6 98%
    Irbesartan (Standard) is the analytical standard of Irbesartan. This product is intended for research and analytical applications. Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
    Irbesartan (Standard)
  • HY-B0204B
    (-)-Pimobendan 118428-37-8 98%
    (-)-Pimobedan is an isomer of pimobedan. It has the property of stereoselective partitioning or distribution into erythrocytes. The clearance of (-)-pimobedan from erythrocytes is significantly lower than that of (+)-pimobedan, which is entirely due to its stereoselective distribution into erythrocytes. This stereoselective property of (-)-pimobedan may explain the phenomenon previously reported that it produces a 1.5-fold greater contractile force than the (+)-isomer in detergent-treated myocardial specimens of guinea pigs and dogs. These properties suggest that (-)-pimobedan may have unique advantages in terms of in vivo distribution and pharmacological action, which may have important implications for its clinical use.
    (-)-Pimobendan
  • HY-B0209S
    Metolazone-d7 2714484-71-4 99.90%
    Metolazone-d7 is deuterium labeled Metolazone. Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.
    Metolazone-d7
  • HY-B0232R
    Dofetilide (Standard) 115256-11-6 98%
    Dofetilide (Standard) is the analytical standard of Dofetilide. This product is intended for research and analytical applications. Dofetilide (UK 68789), as a class III antiarrhythmic agent, is an orally active, potent and specific IKr blocker. Dofetilide can be used for the research of cardiovascular disease.
    Dofetilide (Standard)
  • HY-B0232S
    Dofetilide-d4 1189700-56-8 99.25%
    Dofetilide-d4 is a deuterium labeled Dofetilide. Dofetilide is a class III antiarrhythmic agent.
    Dofetilide-d4
  • HY-B0251S
    Eplerenone-d3 98%
    Eplerenone-d3 is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch.
    Eplerenone-d3
  • HY-B0280A
    (S)-Ranolazine 114246-81-0
    (S)-Ranolazine is the S-isomer of Ranolazine (HY-B0280). Ranolazine is an antianginal agent.
    (S)-Ranolazine
  • HY-B0280S
    Ranolazine-d5 1092804-87-9 98%
    Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor. Antianginal agent.
    Ranolazine-d5
  • HY-B0284A
    Nifedipine hydrochloride 60299-11-8 98%
    Nifedipine hydrochloride is a potent vasodilator with calcium antagonist activity. Nifedipine hydrochloride is a useful antianginal compound that can also lower blood pressure. Nifedipine hydrochloride exhibits comparable antihypertensive properties to some new compounds, especially in calcium channel blockade. Nifedipine hydrochloride is used in biological activity studies to develop new antihypertensive and/or antianginal compounds.
    Nifedipine hydrochloride
  • HY-B0317H
    Amlodipine orotate 914941-70-1
    Amlodipine orotate, an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine orotate can be used for the research of high blood pressure and cancer.
    Amlodipine orotate
  • HY-B0331B
    Enalapril sodium 149404-21-7 98%
    Enalapril (MK-421) sodium is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research.
    Enalapril sodium
  • HY-B0368A
    Captopril hydrochloride 198342-23-3 98%
    Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM.
    Captopril hydrochloride
  • HY-B0368S
    Captopril-d3 1356383-38-4 98%
    Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM.
    Captopril-d3
  • HY-B0375B
    (2S,4S)-Argatroban 189264-03-7 98%
    (2S,4S)-Argatroban ((2S,4S)-MD-805) (Compound 1c) is human thrombin inhibitor with a Ki of 280 μM.
    (2S,4S)-Argatroban
  • HY-B0381S
    Betaxolol-d5 1189957-99-0 98%
    Betaxolol-d5 is the deuterium labeled Betaxolol. Betaxolol is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
    Betaxolol-d5
  • HY-B0387R
    Ibutilide fumarate (Standard) 122647-32-9 98%
    Ibutilide (fumarate) (Standard) is the analytical standard of Ibutilide (fumarate). This product is intended for research and analytical applications. Ibutilide (U70226E) fumarate, an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells.
    Ibutilide fumarate (Standard)
  • HY-B0387S
    Ibutilide-d5 fumarate 98%
    Ibutilide-d5 (fumarate) is deuterium labeled Ibutilide (fumarate).
    Ibutilide-d5 fumarate
  • HY-B0394R
    Atropine sulfate monohydrate (Standard) 5908-99-6
    Atropine (sulfate monohydrate) (Standard) is the analytical standard of Atropine (sulfate monohydrate). This product is intended for research and analytical applications. Atropine (Tropine tropate) sulfate monohydrate is a competitive muscarinic acetylcholine receptor (mAChR) antagonist with IC50 values of 0.39 and 0.71 nM for Human mAChR M4 and Chicken mAChR M4, respectively. Atropine sulfate monohydrate inhibits ACh-induced relaxations in human pulmonary veins. Atropine sulfate monohydrate can be used for research of anti-myopia and bradycardia.
    Atropine sulfate monohydrate (Standard)
  • HY-B0409S
    Clonidine-d4 62497-68-1 98%
    Clonidine-d4 is the deuterium labeled Clonidine. Clonidine hydrochloride is an agonist of α2-adrenoceptor and potent antihypertensive agent.
    Clonidine-d4
  • HY-B0428D
    (E/Z)-Ozagrel sodium 130952-46-4 98%
    (E/Z)-Ozagrel sodium [(E/Z)-OKY-046 sodium] is an EZ configuration mixture of Ozagrel sodium (HY-B0428A). Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases.
    (E/Z)-Ozagrel sodium
Cat. No. Product Name / Synonyms Application Reactivity